Related Experiment Video
Updated: Aug 29, 2025
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Agmatine relieves behavioral impairments in Fragile X mice model
Se Jin Jeon1, Huiyoung Kwon2, Ho Jung Bae3
1Department of Pharmacology and Department of Advanced Translational Medicine, School of Medicine, Konkuk University, Seoul, 05029, Republic of Korea; Department of Integrative Biotechnology, College of Science and Technology, Sahmyook University, Seoul, 01795, Republic of Korea.
Background:
Fragile X syndrome (FXS) is the most common heritable form of neurodevelopmental disorder, which is caused by the loss of fragile X mental retardation protein (FMRP) expression. Despite the unceasing efforts to develop therapeutic agents against FXS based on the pathophysiological changes observed in animal models of FXS and human patients, therapeutic candidates including mGluR signaling modulators have failed to provide sufficient effects. Based on the recent successful demonstration of an endogenous polyamine, agmatine, to improve the autism-like symptoms in the valproic acid animal model of autism, we investigated the effects of agmatine against FXS symptoms using Fmr1 knockout (KO) mice.
Methods:
We used male Fmr1 KO mice for behavioral tests such as marble burying, open-field test, memory tasks, social interaction tests and startle response to confirm the symptoms of FXS. We also checked the electrophysiological profile of neural activity in agmatine-treated Fmr1 KO mice.
Results:
Agmatine reversed the compulsion, learning and memory deficits, hyperactivity, aberrant social interaction, and communication deficit in Fmr1 KO mice while it normalized the aberrant LTP and LTD in the hippocampus.
Conclusions:
The results highlight the potential of agmatine's novel disease-ameliorating effects in FXS, which warrants further studies to ascertain whether these findings translate into clinical effects in FXS patients.
Insights
Agmatine treatment improved autism-like symptoms and cognitive deficits in Fragile X syndrome (FXS) mouse models. This study shows agmatine
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Fragile X syndrome (FXS) is a leading heritable neurodevelopmental disorder due to FMRP loss.
- Current FXS therapies show limited efficacy, necessitating novel treatment strategies.
- Agmatine, an endogenous polyamine, has shown promise in ameliorating autism spectrum disorder symptoms.
Purpose of the Study:
- To investigate the therapeutic potential of agmatine in a mouse model of Fragile X syndrome.
- To evaluate agmatine's effects on FXS-associated behavioral and electrophysiological abnormalities.
Main Methods:
- Utilized Fmr1 knockout (KO) mice, the established model for FXS.
- Conducted a battery of behavioral tests including marble burying, open-field, memory, and social interaction tasks.
- Assessed hippocampal long-term potentiation (LTP) and long-term depression (LTD) in agmatine-treated Fmr1 KO mice.
Main Results:
- Agmatine administration reversed compulsive behaviors, learning and memory deficits in Fmr1 KO mice.
- Agmatine normalized hyperactivity, aberrant social interactions, and communication deficits.
- Electrophysiological analysis revealed that agmatine corrected abnormal LTP and LTD in the hippocampus.
Conclusions:
- Agmatine demonstrates significant potential for ameliorating core symptoms of Fragile X syndrome.
- These findings suggest agmatine as a promising therapeutic candidate for FXS.
- Further research is warranted to explore the clinical translatability of agmatine in FXS patients.
